Mayo Clinic researchers developed AI-powered tools to provide personalized education and radiation therapy for patients with advanced prostate cancer.
These advancements aim to bridge the gap between complex medical data and patient understanding while refining the precision of cancer treatments. By integrating artificial intelligence directly into clinical workflows, the institution seeks to improve outcomes for those facing advanced stages of the disease.
One primary development is MedEduChat, an AI-powered tool integrated into electronic health records. According to a study published Jan. 7, 2026 [2], the tool delivers patient-specific education. This allows patients to receive guidance tailored to their unique medical history and diagnosis rather than relying on generic information.
In addition to patient education, the clinic is advancing treatment delivery through the GEMINI-RT collaboration. Announced Dec. 3, 2025 [1], this partnership with GE HealthCare focuses on integrating AI into personalized radiation therapy. The project utilizes a digital twin approach to help clinicians customize radiation doses and targets for individual patients.
The GEMINI-RT collaboration is built around four [1] pillars of research. These pillars focus on enhancing the accuracy of radiation delivery, and the overall management of advanced cancer care in Rochester, Minnesota.
By combining the MedEduChat education tool with the GEMINI-RT therapy framework, the care team is creating a comprehensive digital ecosystem. This system handles both the informational needs of the patient and the technical requirements of the oncology team, ensuring that the treatment plan is as precise as the patient's understanding of it.
“The tool delivers patient-specific education.”
The shift toward AI-integrated electronic health records and 'digital twin' radiation therapy represents a move toward precision medicine. By automating the delivery of personalized education and refining radiation targets, healthcare providers can reduce human error and improve patient adherence to complex treatment protocols for advanced cancers.
